ArticleCancer discovery2017
Polyclonal Secondary
2 registry-linked trialsOpen access · greenAbstract readCase Reports
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 301 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
301citing papers in PubMed, 1 pooled it
35.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Circulating Tumor DNA (ctDNA) in Genetic Profiling and Clinical Outcomes for Advanced Biliary Tract Cancer (BTC) Patients - A Multicenter, Prospective, Observational Epidemiology Study
Role of Circulating Tumor DNA (ctDNA) in Genetic Profiling and Clinical Outcomes for Advanced Biliary Tract Cancer (BTC) Patients - Prospective, Observational, Epidemiology Study
Who cites it
301 citing papers in PubMed, 1 synthesis or guideline pooled it, 532 citations in OpenAlex.
- Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.Nature reviews. Gastroenterology & hepatology · 2023Guideline
- Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Nature medicine · 2024Trial
- FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Trial
- A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.Investigational new drugs · 2022Trial
- Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Review
- Overcoming Genetic FGFR Resistance in Cholangiocarcinoma: Beyond Genetic Alterations.Digestive diseases and sciences · 2026Article
- Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy.Journal of gastrointestinal oncology · 2026Article
- Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma?Journal of gastrointestinal oncology · 2026Article
- The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives.iScience · 2026Review
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Characteristics of fusion genes in breast cancer.Cancer cell international · 2026Review
- Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.Nature communications · 2026Article
- Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.JCO precision oncology · 2026Review
- Response to letter to the editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic Core.Journal of medicinal chemistry · 2026Article
- Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547.Journal of translational medicine · 2026Article
241 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
32 authors at 5 institutions in 3 countries.
Lipika GoyalMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Supriya K SahaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Leah Y LiuMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Giulia SiravegnaCandiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
Ignaty LeshchinerBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
Leanne G AhronianMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Phuong VuMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Vikram DeshpandeDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Avinash KambadakoneDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Benedetta MussolinCandiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
Stephanie ReyesMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Laura HendersonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Jiaoyuan Elisabeth SunMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Emily E Van SeventerMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Joseph M GurskiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Sabrina BaltschukatNovartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
Barbara Schacher-EngstlerNovartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
Louise BarysNovartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
Christelle StammNovartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
Pascal FuretNovartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland.
David P RyanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
James R StoneDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Gad GetzMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Diana Graus PortaNovartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
Ralph TiedtNovartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
Alberto BardelliCandiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
Dejan JuricMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Ryan B CorcoranMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. azhu@partners.org nbardeesy@partners.org rbcorcoran@partners.org.
Nabeel BardeesyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. azhu@partners.org nbardeesy@partners.org rbcorcoran@partners.org.
Andrew X ZhuMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. azhu@partners.org nbardeesy@partners.org rbcorcoran@partners.org.
Massachusetts General Hospital · USNovartis (Switzerland) · CH5T Torino (Italy) · ITBroad Institute · USCandiolo Cancer Institute · IT
Funding
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MTRANSLATIONAL PHARMACOLOGY COREP50GM107618 · NIGMS · HARVARD MEDICAL SCHOOL · PI MALISZEWSKI, LAURA ELIZABETH · 2014 to 2018
$10.8MTherapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancerR01CA208437 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE · 2016 to 2020
$2.0MCombination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS MK08CA166510 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE · 2013 to 2017
$896kNovel targeted therapies for isocitrate dehydrogenase mutantcholangiocarcinomaK08CA194268 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SAHA, SUPRIYA K · 2015 to 2019
$866kNCI NIH HHS K08 CA166510NCI NIH HHS K08 CA194268NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA208437NIGMS NIH HHS P50 GM107618
Abstract
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion-positive ICC in a phase II trial, but the durability of response was limited in some patients. Here, we report the molecular basis for acquired resistance to BGJ398 in three patients via integrative genomic characterization of cell-free circulating tumor DNA (cfDNA), primary tumors, and metastases. Serial analysis of cfDNA demonstrated multiple recurrent point mutations in the
Indexed as
AdultAntineoplastic AgentsBile Duct NeoplasmsCell Cycle ProteinsCholangiocarcinomaCirculating Tumor DNADrug Resistance, NeoplasmFemaleGene FusionHumansMaleMembrane Transport ProteinsMiddle AgedMutationPhenylurea CompoundsPyrimidinesAntineoplastic AgentsCell Cycle ProteinsCirculating Tumor DNAFGFR2 protein, humanFGFR3 protein, humaninfigratinibMembrane Transport ProteinsOPTN protein, humanPhenylurea CompoundsPyrimidinesReceptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3Transcription Factor TFIIIA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07142226ClinicalTrials.gov
NCT07151118ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.